Gibson Dunn, Latham Steer Ultragenyx's $304M Follow-On
Rare disease drug company Ultragenyx Pharmaceuticals Inc. priced a follow-on offering late Tuesday that raised $304 million to launch and develop new products, represented by Gibson Dunn & Crutcher LLP while...To view the full article, register now.
Already a subscriber? Click here to view full article